| Literature DB >> 34284743 |
Hongzhi Liu1, Lianku Lin1, Ziguo Lin1, Yifan Chen1, Qizhen Huang1, Lei Ding2, Jianying Lou3, Shuguo Zheng4, Xinyu Bi5, Jianming Wang6, Wei Guo7, Fuyu Li8, Jian Wang9, Yamin Zheng10, Jingdong Li11, Shi Cheng12, Weiping Zhou13, Zhangjun Cheng14, Yongyi Zeng15,16.
Abstract
BACKGROUND: The objective of this study was to investigate the survival outcomes of surgical margin width in intrahepatic cholangiocarcinoma (ICC).Entities:
Keywords: Disease-free survival; Intrahepatic cholangiocarcinoma; Margin width; Overall survival
Year: 2021 PMID: 34284743 PMCID: PMC8293518 DOI: 10.1186/s12885-021-08560-7
Source DB: PubMed Journal: BMC Cancer ISSN: 1471-2407 Impact factor: 4.430
Fig. 1Flowchart of patients’ enrollment
Clinicopathological characteristics before and after PSM
| Before PSM | After PSM | |||||
|---|---|---|---|---|---|---|
| Wide | Narrow | Wide | Narrow | |||
| ( | ( | ( | ( | |||
| Male | 103 (52.8%) | 184 (65.0%) | 0.010 | 51 (64.6%) | 47 (59.5%) | 0.623 |
| Female | 92 (47.2%) | 99 (35.0%) | 28 (35.4%) | 32 (40.5%) | ||
| ≤ 60 years | 115(59.0%) | 177(62.5%) | 0.489 | 42(53.2%) | 50(63.3%) | 0.259 |
| > 60 years | 80(41.0%) | 106(7.5%) | 37(46.8%) | 29(36.7%) | ||
| Negative | 144 (73.8%) | 184 (65.0%) | 0.052 | 55(69.6%) | 59(74.7%) | 0.594 |
| Positive | 51 (26.2%) | 99 (35.0%) | 24(30.4%) | 20(25.3%) | ||
| ≤ 200 U/mL | 136 (69.7%) | 253 (89.4%) | < 0.001 | 63(79.7%) | 65(82.3%) | 0.839 |
| > 200 U/mL | 59 (30.3%) | 30 (10.6%) | 16(20.3%) | 14(17.7%) | ||
| ≤ 5 μg/L | 125 (64.1%) | 234 (82.7%) | < 0.001 | 56(70.9%) | 56(70.9%) | 1.000 |
| > 5 μg/L | 70 (35.9%) | 49 (17.3%) | 23(29.1%) | 23(29.1%) | ||
| ≤ 400 mL | 141(72.3%) | 229(80.9%) | 0.036 | 61(77.2%) | 57(72.2%) | 0.583 |
| >400 mL | 54(27.7%) | 54(19.1%) | 18(22.8%) | 22(27.8%) | ||
| No | 148(75.9%) | 246(86.9%) | 0.003 | 60(75.9%) | 61(77.2%) | 1.000 |
| Yes | 47(24.1%) | 37(13.1%) | 19(24.1%) | 18(22.8%) | ||
| No | 163 (83.6%) | 281 (99.3%) | < 0.001 | 76 (96.2%) | 77 (97.5%) | 1.000 |
| Yes | 32 (16.4%) | 2 (0.7%) | 3 (3.8%) | 2 (2.5%) | ||
| No | 72 (36.9%) | 80 (28.3%) | 0.058 | 32(40.5%) | 31(39.2%) | 1.000 |
| Yes | 123 (63.1%) | 203(71.7%) | 47(59.5%) | 48(60.8%) | ||
| No | 137 (70.3%) | 233 (82.3%) | 0.003 | 60 (75.9%) | 59 (74.7%) | 1.000 |
| Yes | 58 (29.7%) | 50 (17.7%) | 19 (24.1%) | 20 (25.3%) | ||
| ≤ 5 cm | 86 (44.1%) | 94 (33.2%) | 0.020 | 37(46.8%) | 34(43.0%) | 0.749 |
| > 5 cm | 109 (55.9%) | 189 (66.8%) | 42(53.2%) | 45(57.0%) | ||
| Single | 163 (83.6%) | 181 (64.0%) | < 0.001 | 61(77.2%) | 60(75.9%) | 1.000 |
| Multiple | 32 (16.4%) | 102 (36.0%) | 18(22.8%) | 19(24.1%) | ||
| No | 140 (71.8%) | 250 (88.3%) | < 0.001 | 67 (84.8%) | 69 (87.3%) | 0.818 |
| Yes | 55 (28.2%) | 33 (11.7%) | 12 (15.2%) | 10 (12.7%) | ||
| No | 38 (19.5%) | 116 (41.0%) | < 0.001 | 28(35.4%) | 19(24.1%) | 0.164 |
| Yes | 157 (80.5%) | 167 (59.0%) | 51(64.6%) | 60(75.9%) | ||
| Well &Moderate | 139 (71.3%) | 236 (83.4%) | 0.002 | 64(81.0%) | 60(75.9%) | 0.561 |
| Poor | 56 (28.7%) | 47 (16.6%) | 15(19.0%) | 19(24.1%) | ||
| No | 170 (87.2%) | 181 (64.0%) | < 0.001 | 65(82.3%) | 62(78.5%) | 0.689 |
| Yes | 25 (12.8%) | 102 (36.0%) | 14(17.7%) | 17(21.5%) | ||
| No | 165 (84.6%) | 254 (89.8%) | 0.124 | 72(91.1%) | 68(86.1%) | 0.453 |
| Yes | 30 (15.4%) | 29 (10.2%) | 7(8.9%) | 11(13.9%) | ||
| No | 164 (84.1%) | 261 (92.2%) | 0.008 | 66(83.5%) | 69(87.3%) | 0.652 |
| Yes | 31 (15.9%) | 22 (7.8%) | 13(16.5%) | 10(12.7%) | ||
| No | 141(72.3%) | 240(84.8%) | 0.001 | 64(81.0%) | 66(83.5%) | 0.835 |
| Yes | 54(27.7%) | 43(15.2%) | 15(19.0%) | 13(16.5%) | ||
Abbreviations: PSM propensity score matching, CEA carcinoembryonic antigen, CA19–9 carbohydrate antigen 19–9, HBsAg hepatitis B surface antigen, MVI microvascular invasion, p-AT postoperative adjuvant therapy
Fig. 2Overall survival (A, C) and disease-free survival (B, D) before and after propensity score matching of patients underwent wide margin hepatectomy and narrow margin hepatectomy for intrahepatic cholangiocarcinoma
Univariate and multivariate analysis of overall survival and disease-free survival for patients with intrahepatic cholangiocarcinoma after PSM
| Characteristic | Variables | OS | DFS | |||||||
|---|---|---|---|---|---|---|---|---|---|---|
| Univariate analysis | Multivariate analysis | Univariate analysis | Multivariate analysis | |||||||
| HR (95% | HR (95% | HR (95% | HR (95% | |||||||
| Gender | Female vs Male | 0.72(0.45–1.14) | 0.158 | 0.77(0.51–1.16) | 0.217 | |||||
| Age (y) | ≤60 vs > 60 | 0.92(0.59–1.43) | 0.706 | 0.71(0.48–1.06) | 0.098 | |||||
| HBsAg | Negative vs Positive 1.08(0.67–1.75) | 0.750 | 1.08(0.70–1.66) | 0.738 | ||||||
| ECOG score | ≤2 vs > 2 | 1.00(0.64–1.55) | 0.986 | 0.80(0.54–1.18) | 0.255 | |||||
| CA19–9 (U/ml) | ≤200 vs > 200 | 1.23(0.71–2.14) | 0.458 | 0.88(0.53–1.47) | 0.625 | |||||
| CEA (ng/ml) | ≤5 vs > 5 | 1.03(0.63–1.67) | 0.912 | 0.91(0.59–1.39) | 0.653 | |||||
| Blood loss (ml) | ≤400 vs > 400 | 1.02(0.61–1.71) | 0.947 | 0.74(0.46–1.19) | 0.216 | |||||
| Transfusion | No vs Yes | 1.15(0.69–1.90) | 0.600 | 0.61(0.37–1.02) | 0.058 | |||||
| No vs Yes | 1.39(0.34–5.70) | 0.644 | 0.74(0.18–3.00) | 0.671 | ||||||
| Major hepatectomy | No vs Yes | 1.34(0.84–2.15) | 0.215 | 1.02(0.69–1.52) | 0.920 | |||||
| No vs Yes | 1.06(0.65–1.73) | 0.809 | 0.87(0.56–1.37) | 0.562 | ||||||
| Resection margin (cm) | ≤1 vs > 1 | 1.65(1.06–2.58) | 0.026 | 1.60(1.03–2.50) | 0.039 | 1.49(1.01–2.20) | 0.046 | |||
| Tumor size (cm) | ≤5 vs > 5 | 1.33(0.85–2.08) | 0.214 | 1.15(0.77–1.70) | 0.497 | |||||
| Tumor number | Solitary vs Multiple | 1.31(0.81–2.12) | 0.267 | 1.14(0.73–1.80) | 0.558 | |||||
| Lymph node invasion | No vs Yes | 2.03(1.15–3.57) | 0.014 | 2.24(1.27–3.95) | 0.005 | 1.15(0.65–2.02) | 0.638 | |||
| Mass-forming | No vs Yes | 1.17(0.73–1.87) | 0.524 | 1.33(0.87–2.05) | 0.187 | |||||
| Tumor differentiation | Well &Moderate vs Poor | 1.33(0.85–2.08) | 0.214 | 0.80(0.48–1.34) | 0.399 | |||||
| Satellite | No vs Yes | 1.27(0.77–2.11) | 0.352 | 1.32(0.84–2.09) | 0.231 | |||||
| MVI | No vs Yes | 2.03(1.12–3.69) | 0.02 | 2.42(1.39–4.22) | 0.002 | 2.67(1.50–4.74) | 0.001 | |||
| Perineural invasion | No vs Yes | 0.94(0.50–1.79) | 0.860 | 0.69(0.38–1.26) | 0.232 | |||||
| p-AT | No vs Yes | 0.38(0.18–0.83) | 0.016 | 0.39(0.18–0.85) | 0.018 | 0.73(0.43–1.24) | 0.244 | |||
Abbreviations: PSM propensity score matching, CEA carcinoembryonic antigen, CA19–9 carbohydrate antigen 19–9, HBsAg hepatitis B surface antigen, MVI microvascular invasion, p-AT postoperative adjuvant therapy, OS overall survival, DFS disease-free survival, HR hazard ratio
Fig. 3Forest plot of subgroup analysis stratified by risk factors according to disease-free survival
Fig. 4Forest plot of subgroup analysis stratified by risk factors according to overall survival
Fig. 5Subgroup analyses of overall survival and disease-free survival in ICC patients with AJCC8th stage I (A, D), stage II (B, E), and stage III (C, F) who underwent wide margin hepatectomy and narrow margin hepatectomy